Persistent gastroesophageal reflux disease symptoms on standard proton-pump inhibitor therapy.
Eight patients with refractory GERD symptoms were controlled over a mean of 15.4 years only by the addition of a benzodiazepine to once-daily or twice-daily PPI therapy. In selected patients with refractory GERD, as defined by continued reflux symptoms despite twice-daily PPIs, the addition of a benzodiazepine to the PPI regimen may provide additional control of GERD symptoms.
Sontag
Stephen J
SJ
Veterans Affairs Medical Center, 5th Avenue and Roosevelt Road, Building #1, Room B321, Hines, IL 60141, USA.
D000328:Adult; D000368:Aged; D003975:Diazepam / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D006993:Hypnotics and Sedatives; D054328:Proton Pump Inhibitors; D009853:Omeprazole; D003975:Diazepam